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Vaccination  is at  present  the  most  efﬁcient  way  of  preventing  inﬂuenza  infections.  Currently  used inactiv-
ated inﬂuenza  vaccines  can  induce  virus-neutralizing  antibodies  that are  protective  against  a particular
inﬂuenza  strain,  but  hamper  the  induction  of  cross-protective  T-cell  responses  to later  infections.  Thus,
inﬂuenza  vaccines  need  to be updated  annually  in order  to  confer  protection  against  circulating  inﬂuenza
strains.  This study  aims  at  developing  an efﬁcient  vaccine  that  can induce  broader  protection  against
inﬂuenza.  For  this  purpose,  we  have  used  the  highly  conserved  nucleoprotein  (NP)  from  an inﬂuenza
A  virus  subtype  H7N7  strain,  and  inserted  it into  a  vaccine  format  that  targets  an  antigen  directly  to
relevant  antigen  presenting  cells  (APCs).  The  vaccine  format  consists  of  bivalent  antigenic  and  targeting
units,  linked  via  an  Ig-based  dimerization  unit.  In this  study,  NP  was  linked  to MIP-1,  a chemokine  that
targets  the  linked  antigen  to  chemokine  receptors  1, 3 and  5  expressed  on various  APCs.  The  vaccine  pro-
tein  was  indirectly  delivered  by  DNA.  Mice were  vaccinated  intradermally  with  plasmids,  in  combination
with  electroporation  to  enhance  cellular  uptake  of  DNA.  We  found  that  a single  DNA vaccination  was
sufﬁcient  for  induction  of  both  antibody  and  T cell responses  in BALB/c  mice.  Targeting  of  nucleoprotein
to  chemokine  receptors  enhanced  T cell  responses  but  not  antibody  responses.  Moreover,  a single  dose  of
MIP1-NP  conferred  protection  in  BALB/c  mice  against  a lethal  challenge  with  an  H1N1  inﬂuenza  virus.
The  observed  cross-protection  was  mediated  by CD8+ T cells.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Inﬂuenza epidemics annually cause thousands of deaths and
evere illness in millions of people worldwide [1]. Conventional
rophylactic inﬂuenza vaccines typically induce protection [2], but
ave a limitation in that they only induce strain-speciﬁc antibodies.
his is a problem since the surface proteins (hemagglutinin, neu-
aminidase) on inﬂuenza virus particles are subject to antigenic
rift, and a consequence is that the antigenic determinants may
hange so that last year’s antibodies do not recognize this year’s
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
inﬂuenza strain. Thus, inﬂuenza vaccines have to be updated every
year. Furthermore, in the event of a pandemic, the long produc-
tion time required for conventional vaccines represents an obstacle
towards efﬁcient protection of the population.
Natural infection with inﬂuenza A viruses induces both humoral
and cellular immunity. Unlike neutralizing antibodies against sur-
face proteins, T cell immunity cannot block the initial viral entry
into somatic cells. However, activated T cells can selectively kill
virus-infected cells [3], and the presence of CD8+ T cells speciﬁc for
conserved viral epitopes have been shown to correlate with less
severe illness during natural infection in humans [4]. T cell epitopes
on internal proteins are commonly highly conserved between dif-
ferent strains of inﬂuenza viruses [5–7], and a number of studies
in mice and nonhuman primates have shown that heterosubtypic
immunity is mediated predominantly by cross-reactive cytotoxic
CD8+ T cells [8–12]. Such T cells can even confer heterosubtypic
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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rotection in individuals lacking pre-existing antibodies [6]. Impor-
antly, vaccine-induced T cells could thus confer some protection
gainst pandemic inﬂuenza. Moreover, vaccine induced T cells
ould play a role in protection against inﬂuenza in elderly indi-
iduals subject to immune exhaustion [13–16].
Long-lasting cellular immunity is directed predominantly
gainst conserved, internal viral proteins, such as nucleoprotein
NP) [17,18]. NP is a major component of the ribonucleoprotein
RNP) complexes. The RNP consists of RNA, multiple copies of
P, and polymerase subunits (PB1, PB2 and PA), together form-
ng a large loop that is twisted into a helical rod-like structure
19,20]. NP plays regulatory roles in transcription, replication,
nd virus maturation [21], and it is one of the most conserved
roteins among inﬂuenza A viruses with >90% protein sequence
omology [22,23]. Correspondingly, several immunization stud-
es with NP have shown induction of effective immune responses
nd protection against various inﬂuenza A subtypes [5,6,24–27].
owever, protection is dependent on large vaccine doses and
ultiple immunizations [28], and it has been difﬁcult to achieve
ufﬁciently potent immune responses to confer protection against
ighly pathogenic H5N1-viruses [29,30].
Previously, we have demonstrated that the selective target-
ng of antigen to APC increases immune responses [31–34]. In
act, such targeting may  be a key to overcome the hurdle of low
mmunogenicity that is often observed with subunit DNA vaccina-
ion. Here, we have investigated whether targeting of a conserved
nﬂuenza antigen, NP, to chemokine receptors can enhance rel-
vant T cell responses against inﬂuenza. To this end, NP was
nserted into the previously described vaccine format, consisting
f bivalent antigenic and targeting units that are linked through
n Ig-based dimerization unit [31,33]. As targeting unit, we  used
acrophage inﬂammatory protein-1 alpha (MIP-1) that binds
hemokine receptors 1, 3 and 5 (CCR1/3/5), a choice based on previ-
us results demonstrating that MIP-1 is a particularly well suited
argeting unit for efﬁcient induction of CD8+/Th1 T cell responses
33]. CCR1/3/5 are expressed on various cell types such as dendritic
ells, monocytes, macrophages, NK cells, eosinophils, basophils,
eurons, platelets, ﬁbroblasts, microglial cells, and endothelial cells
35]. MIP-1  is a small pro-inﬂammatory chemokine of the CC sub-
amily [36], and is involved in recruiting CCR1/3/5+ cells to sites of
nfection. Here, we demonstrate that a single vaccination with a
imeric MIP1-NP vaccine can enhance protection against a lethal
etero challenge with inﬂuenza. The vaccine-induced protection is
ediated mainly by CD8+ T cells.
. Materials and methods
.1. Mice and cell lines
Six to eight weeks old female BALB/c mice were purchased from
aconic (Ry, Denmark) and housed under minimal disease condi-
ions. All animal experiments were approved by the Norwegian
nimal Research Authority (NARA). The HEK293E [37] cell line was
urchased from ATCC (Manassas, VA, USA). MDCK cells were a kind
ift from Tone Fredsvik Gregers at the University of Oslo.
.2. Construction of vaccine molecules
Nucleoprotein from the inﬂuenza virus A/whooper
wan/Norway/10 438/2006 (H7N7) was ampliﬁed by RT-PCR
sing NP-speciﬁc primers [38] and inserted into a pCR4-TOPO
ector (Invitrogen). The gene was picked up by PCR with ﬂanking
ﬁI-sites (underlined): 5′ NP: GGC CTC GGT GGC CTGGCG TCT CAA
G; 3′ NP: CCG GCC CTG CAG GCCTCA CTT TAA TTG TC, and the
ene inserted into the restriction sites of previously described 33 (2015) 6988–6996 6989
pLNOH2 expression vectors [31,33]. To allow for a comparison of
responses in the absence of the bivalent vaccine format, a vaccine
containing only the antigenic unit (NP) was prepared using the
3′NP primer described above and 5′: CAC AGG TGT GCA TTC CGC
GTC TCA AGG C (AleI and BsmI restriction sites are underlined).
Molecular cloning was  veriﬁed by restriction enzyme digest and
sequencing.
2.3. Western blot
Supernatants of HEK293E cells transiently transfected with
plasmids encoding the different vaccine molecules were up-
concentrated and run on a Novex 4–12% Tris–glycine gel
(Invitrogen) under non-reducing conditions, together with Spectra
Multicolor Broad Range Protein Ladder (Thermo Scientiﬁc). Follow-
ing blotting (Immuno-Blot PVDF membrane, BioRad), the mem-
brane was  blocked overnight at 4 ◦C (2% Membrane Blocking agent,
RPN212SV, GE Healthcare) and incubated with biotinylated mAb
against IgG Fc (1:10,000) (HP-6017, Sigma Aldrich, Germany). After
3 washes with PBS/0.1% Tween 20, the membrane was incubated
with Streptavidin-HRP (1:10,000) (GE Healthcare), developed with
ECL (Amersham ECL Select, GE Healthcare), and analyzed on G:Box
(SYNGENE, UK) with GeneSys software. For detection of NP alone,
1 g of puriﬁed protein was  run on a Novex 4–12% Tris–glycine
gel under reducing conditions, blotted and blocked as above. Next,
the membrane was incubated with NP HRP-conjugated C43 mAb
(1:10,000) (Abcam, UK), and developed as above.
2.4. Chemotaxis assay
The chemotactic integrity of the vaccine proteins was  assessed
as previously described [39]. Brieﬂy, one million Esb/MP cells
were added to the upper chamber of a 24-well Transwell® plate
(5.0 m pore size) (Corning Laboratories, Corning, NY, USA), while
the lower chambers were ﬁlled with serially diluted supernatants
from HEK293E cells transiently transfected with 1 g of plasmids
encoding the different vaccine molecules, or recombinant LD78
(20 ng/ml). The plates were incubated for 2 h at 37 ◦C in 5% CO2,
and cell count determined with a BD FACSCalibur (BD Biosciences,
San Jose, CA, USA).
2.5. ELISA for detection of NP vaccine proteins
Ninety-six well plates (Coastar 3590) were coated with either
anti-NP mAb  (1 g/ml) (C43, Abcam, UK) or mouse anti-human IgG
(CH3 domain) (2 g/ml) (MCA878G, AbD Serotec, Oxford, UK), and
blocked with PBS/BSA for 1 h at room temperature (RT). Follow-
ing washing, supernatants of HEK293E cells transiently transfected
with 1 g vaccine encoding plasmids were added into wells in trip-
licates, and incubated for 2 h at RT. Plates were washed, and vaccine
proteins detected by incubation with either biotinylated anti-NP
mAb  (1 g/ml) (H16-L10-4R5, ATCC: HB-65) or biotinylated mAb
against IgG Fc (1 g/ml) (HP-6017, Sigma Aldrich, Germany) for
2 h at RT, and then Streptavidin alkaline phospatase (1:3000) (GE
Healthcare, USA) for 45 min  at RT. Development was performed
with Phosphatase substrate (P4744-10G, Sigma Aldrich, Germany),
and plates were read at 405 nm with a Tecan reader using the
Magellan v5.03 program.
2.6. ELISA for detection of serum anti-NP antibodies
Blood samples were collected from mice and sera isolated.
Ninety-six well plates were coated overnight with recombinant NP-
H7N7 (0.5 g/ml in PBS/azide) (ESB-EP325878IMI, CUSABIO, China)
or inactivated inﬂuenza A/Puerto Rico/8/1934 (H1N1) (Charles
River Laboratories), blocked as above, and incubated over night at
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◦C with diluted serum samples from individual mice. Next, plates
ere incubated for 2 h at RT with either of the following biotiny-
ated antibodies (1 g/ml): anti-mouse IgG (Fc speciﬁc, A1418,
igma Aldrich, Germany), anti IgG1 (553599, BD Pharmingen), anti
gG2a (553502, BD Pharmingen), and developed as described above.
.7. Virus
The inﬂuenza virus A/Puerto Rico/8/34 (Mt.Sinai sub-strain)
H1N1) (PR8) was propagated by inoculation into the allantoic cav-
ty of 10-day-old embryonated chicken eggs. Identity of the injected
iruses was conﬁrmed by sequencing of HA. Allantoic ﬂuid was
arvested, and conﬁrmed negative for bacterial contaminations.
CID50 was determined.
.8. Mouse immunization
BALB/c mice were anaesthetized, shaved in the lower back
egion, and vaccinated by intradermal (i.d.) administration of 25 g
lasmid DNA dissolved in NaCl on each ﬂank of the animal, fol-
owed immediately by skin electroporation (EP) with Derma Vax
Cellectis, Paris, France). Plasmids were puriﬁed by Endofree Qiagen
it.
.9. Inﬂuenza challenge
Mice were challenged 2 or 4 weeks after immunization by
ntranasal (i.n.) inoculation of 5 × LD50 PR8 in 10 l into each nos-
ril. Mice were monitored for weight loss, with an endpoint of 20%
eight reduction, as required by the Norwegian Animal Research
uthority (NARA).
.10. Microneutralization assay
Equal serum volumes from individual mice (n = 10 mice/group)
ere pooled and treated with receptor-destroying enzyme (RDE).
wo-fold dilutions in virus diluent (DMEM supplemented with 1%
ovine albumin fraction V, antibiotics, and 0.02 M HEPES) were set
p in triplicates in 96-well plates. Four control wells of virus in
iluent and diluent alone (cells only) were included on each plate.
ifty microliters 100 TCID50 virus was added to each well, and
lates were incubated for 2 h at 37 ◦C in a 5% CO2 humidiﬁed atmo-
phere. MDCK cells (2 × 105) were added to each well, followed
y incubation for 20 h at 37 ◦C and 5% CO2. The monolayers were
ashed with PBS, ﬁxed in cold 80% acetone for 10 min, and viral
roteins detected by an ELISA using biotinylated mAb  against the
nﬂuenza nucleoprotein (HB-65; ATCC) and Streptavidin-alkaline
hosphatase. Plates were read as described above, with a Tecan
eader using the Magellan v5.03 program.
.11. ELISPOT assay
ELISpot assay was performed using the ELISpotPLUS for MOUSE
FN kit (Mabtech, Sweden). Brieﬂy, 2 or 4 weeks after a single
mmunization, spleens were isolated and single-cell suspensions
n = 6 mice/group) prepared by mashing individual spleens through
 cell strainer. The suspended cells were incubated 7 min  on ice
ith ACT lysis buffer and washed three times with RPMI. Cells
ere plated in triplicates on previously washed and blocked (RPMI
ith 10% FCS and supplements) multiscreen plates. Cells were
timulated (4 g/ml) with either NP peptide mix  (Swiss prot ID:
91743, JPT Peptide Technologies GmbH, Germany), class I pep-
ide (NP147–155, TYQRTRALV, Proimmune, UK), class II peptide
NP55–69, RLIQNSLTIERMVLS, Proimmune, UK), irrelevant mix  (HA,
X88, Proimmune, UK), an irrelevant control peptide (HA, SVSS-
ERFEIFPK, Proimmune, UK), or no peptide, for 18 h at 37 ◦C in 5% 33 (2015) 6988–6996
CO2 humidiﬁed atmosphere. Next, cells were incubated with detec-
tion mAb  (R4-6A2-bio) and Streptavidin-alkaline phosphatase, and
IFN—producing cells detected by the BCIP/NBT-plus substrate
solution. An automated analysis of spots was performed using the
CTL-ImmunoSpot® S6 Micro Analyzer and the ImmunoSpot 5.1.34
software.
2.12. T cell depletion
Mice were vaccinated once as described above (n = 5
mice/group). From day 11 and until termination of the exper-
iment, mice were injected every other day intraperitoneally
(i.p.) with either 100 g of puriﬁed anti-CD4 (GK1.5, ATCC),
100 g anti-CD8 (TIB105, ATCC), or both. On day 14, mice were
challenged with PR8 and monitored for weight loss. On the day
of termination, mice were euthanized by cervical dislocation
and spleens collected for FACS evaluation of in vivo depletion
efﬁcacy: Splenocytes were FcR-blocked by incubation with 60%
heat-aggregated rat serum for 45 min  on ice, and stained with Abs
against CD8 (Paciﬁc Blue—conjugated, 558106; BD Biosciences),
CD4 (allophycocyanin-conjugated, 1540-11; Southern Biotechnol-
ogy Associates), CD14 (FITC-conjugated, 553739, BD Pharmingen),
CD19 (FITC-conjugated, 35-0193-U100, TONBOBioscience) and
CD3 (PE-conjugated, 1530-09C; Southern Biotechnology Asso-
ciates). Cells were ﬁxed with 2% paraformaldehyde and analyzed
on LSR II ﬂow cytometer (BD) with FlowJo (Treestar, USA).
2.13. T cell transfer
Mice were vaccinated once as described above. At day 14, mice
were sacriﬁced and spleens collected. CD4+ T cells were isolated by
Dynabeads® UntouchedTM Mouse CD4 Cells Kit (Invitrogen), and
CD8+ T cells by Dynabeads® UntouchedTM Mouse CD8  Cells Kit
(Invitrogen). Next, 106 cells were transferred i.p. to naïve BALB/c
mice (n = 6 mice/group) that were challenged 24 h later with PR8.
Body weight was  monitored, and mice losing >20% of their initial
weight were euthanized and scored as dead. Purity of transferred
cells was determined by FACS analyses as above (depletion exper-
iment).
2.14. Statistical analyzes
Statistical analyzes were performed using either one-tailed
Mann–Whitney or two-way ANOVA and Bonferroni multiple
comparison test (GraphPad Software). For the T cell depletion
experiment, the statistical testing was  performed on data from
day 7. For the T cell transfer experiment, the statistical testing was
performed on data from day 9. The  level was set to 0.05 for all
analyzes.
3. Results
3.1. Construction and characterization of CCR1/3/5-targeted
inﬂuenza vaccine
The vaccine molecules employed are DNA-encoded homod-
imeric vaccine proteins, each chain consisting of: (1) a targeting
unit; (2) a dimerization unit derived from the hinge and CH3 exons
of human IgG3; and (3) an antigenic unit [31,32]. In the ER, two
chains will dimerize to form a homodimeric structure, allowing
a bivalent display of targeting units and antigens (Fig. 1A). We
have here inserted NP from inﬂuenza A/whooper swan/Norway/10
438/2006 (H7N7) as antigen into the vaccine constructs, and linked
it to the chemokine MIP-1 via the dimerization unit. The targeted
vaccine is denoted MIP1-NP. In order to measure the effect of
MIP1-targeting, we  prepared a control vaccine in which MIP-1
M. Baranowska et al. / Vaccine 33 (2015) 6988–6996 6991
Fig. 1. Characterization of NP-containing vaccine molecules. (A) Schematic structure of a dimeric vaccine protein. As targeting units the chemokine MIP-1,  or a scFv against
the  hapten NIP (NIP, non-targeted control), were used. Inﬂuenza nucleoprotein (NP) was linked to the targeting units via a homo-dimerization unit containing a shortened
Ig  hinge and a h3 CH3 domain. The vaccine molecules were delivered by DNA vaccination, and transfected cells secreted the vaccine proteins. (B) Supernatants of transfected
293E  cells were examined by sandwich ELISA, with NP mAb (C43, ab128193) as coat and biotinylated NP antibody (H16-L10-4R5) for detection. (C) Supernatants of
transfected 293E cells were examined by a Western blot where dimeric vaccine molecules were detected with biotinylated hIgG (Fc speciﬁc) mAb (HP6017-bio). The
theoretical molecular weight of dimeric MIP1-NP was  calculated to ∼164 kDa, whereas dimeric NIP-NP was  calculated to ∼200 kDa. (D) In vitro chemotaxis of Esb/MP
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as replaced with a single chain variable fragment (scFv) speciﬁc
or the synthetic hapten 4-hydroxy-3-iodo-5-nitrophenylacetic
cid (NIP) (NIP-NP). We  also prepared a vaccine containing NP
lone, without the homodimeric vaccine backbone (NP alone). The
accine constructs were inserted into the pLNOH2 vector, and
xpressed under the control of a CMV  promoter and an Ig-derived
ignal sequence [32].
Plasmids encoding the constructed vaccine molecules were
ransiently transfected into HEK293E cells, and the secreted pro-
eins evaluated by sandwich ELISA and Western Blotting (Fig. 1B
nd C, Fig. S1). Cells transfected with either MIP1-NP or NIP-
P-containing plasmids secreted dimeric vaccine proteins with the
xpected sizes and properties. NP alone was also secreted (Fig. 1B),
nd had a correct size by Western blotting (Fig. S1B). The func-
ionality of the MIP-1  targeting unit in MIP1-NP was further
onﬁrmed in an in vitro chemotaxis assay of Esb/MP cells (Fig. 1D).
he non-targeted control (NIP-NP) had no activity in this assay.
.2. Targeting of NP to CCR 1/3/5 results in production of NP
peciﬁc antibodiesBALB/c mice were injected once intradermally (i.d.) with 25 g
f the different DNA vaccines, immediately followed by elec-
roporation (EP) of the injected site. Electroporation increases
ransfection efﬁcacy [40,41] and enhances production of secretedd increase in the number of migrating cells in the presence of vaccine proteins over
vaccine proteins [32] that target CCR1/3/5 on APCs [31]. A sin-
gle vaccination with DNA encoding either MIP1-NP, or NIP-NP,
or NP alone, was  sufﬁcient for induction of antibody responses
against recombinant NP as measured in ELISA (Fig. 2A–C). MIP1-
NP induced signiﬁcantly higher IgG2a responses as compared to
NP alone and NIP-NP (Fig. 2C), whereas there were no signiﬁ-
cant differences in the measured total IgG levels or IgG1 (Fig. 2A
and B). Despite the observed increases in antibody titers, neither
of the vaccines induced antibodies that could neutralize virus in a
microneutralization assay performed with sera from week 4 and
14 after immunization (Fig. 2D and E). As a positive control in this
assay, we  used a previously described vaccine that targets inﬂuenza
hemagglutinin (HA) to MHC  class II molecules on APCs [34]; this
vaccine as expected induced high amounts of neutralizing anti-
HA antibodies (Fig. 2D and E). This difference in antibody inducing
capacity is likely due to the localization of NP and HA within viral
particles. Accordingly, antibodies against an internal protein such
as NP are not expected to be able to neutralize virus.
3.3. Vaccination with MIP1˛-NP protects mice from
heterochallenge with a different inﬂuenza virusAs previously described, NP is highly conserved between dif-
ferent strains of inﬂuenza. Two  of the more distantly related NP
proteins are those of inﬂuenza A/PR/8/1934 (H1N1) (PR8) and
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ross-protective potential induced by vaccination with the vari-
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signs of disease, but mice receiving MIP1-NP recovered earlier
from infection (Fig. 3A and C). Interestingly, the importance of tar-
geting to CCR1/3/5 increased with time after vaccination, and mice
receiving MIP1-NP displayed signiﬁcantly reduced weight loss
after viral challenge at day 28, as compared to non-targeted controls
(Fig. 3C). The same tendency was  seen when mice were challenged
14 days after vaccination, although results were not signiﬁcant.
When assessing survival, mice receiving MIP1-NP displayed an
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ncreased degree of protection compared to the non-targeted con-
rols when challenged either 14 or 28 days after vaccination (Fig. 3B
nd D). Taken together, these data demonstrate that targeting of
P to CCR1/3/5 improves heteroprotection against challenge with
nﬂuenza virus.
.4. Vaccination with MIP1˛-NP enhances T cell responses
Despite the lack of neutralizing antibodies (Fig. 2D and E),
IP1-NP immunized mice were protected against heterochal-
enge with inﬂuenza PR8 (Fig. 3). The antibodies were conﬁrmed to
e cross-reactive, as an ELISA against PR8 showed similar trends to
hat observed against recombinant NP from an H7N7 strain (Fig. S3).
n neither case did the observed protection correlate with the differ-
nt levels of antibodies observed (Fig. 2A–C, S3). Thus, we decided to
nvestigate the role of T cells in induction of immunity. BALB/c mice
ere vaccinated once with the DNA encoded vaccines followed by
P, and spleens harvested 15 days (Fig. 4A) or 28 days (Fig. 4B)
ater. Splenocytes were then stimulated with either a pooled NP
eptide mix, a class-I restricted NP peptide (TYQRTRALV), a class-
I restricted NP peptide (RLIQNSLTIERMVLS), or control peptides
including an HA mix), and an IFN ELISpot assay was performed.
wo weeks after vaccination, all vaccinated groups had developed T
ell responses that were signiﬁcantly elevated above saline-treated
ice. There was an additional elevation in mice receiving MIP1-
P, but this increase was not statistically signiﬁcant as compared
o non-targeted controls (Fig. 4A). Examination of T cell responses
8 days after vaccination revealed a more clear picture (Fig. 4B).
plenocytes from mice receiving MIP1-NP were secreting signiﬁ-
antly higher levels of IFN as compared to non-targeted controls,
articularly after stimulation with the class I peptide TYQRTRALV,
ut also after stimulation with the mixed NP peptides. There was
o signiﬁcant difference between MIP1-NP and NIP-NP after
e-stimulation with the class II peptide RLIQNSLTIERMVLS, but
here was a signiﬁcant difference between MIP1-NP and NP alone.
nterestingly, the differences in IFN secretion closely resembled
esistance to the viral heterochallenge as induced by immuniza-
ion. In summary, the T cell-stimulatory effect of targeting NP to
CR1/3/5 increases from day 14 to 28, after a single DNA immuni-
ation. 33 (2015) 6988–6996 6993
3.5. Enhanced T cell responses following DNA immunization
contribute to protection against inﬂuenza challenge
To further investigate the contribution of T cells to protection,
BALB/c mice were vaccinated once with DNA plasmids encoding
MIP1-NP. Starting at day 11 after immunization, animals were
treated with depleting monoclonal antibodies (mAbs) against CD8,
CD4, or both. A group of mice immunized with NaCl, and no mAb
treatment, was also included. The efﬁcacy of depletion was  con-
ﬁrmed by FACS analyzes (Fig. S4A). On day 14, mice received a lethal
dose of PR8 virus (Fig. 5A and B). The delivery of depleting antibod-
ies against both CD4 and CD8 completely abolished protection, and
mice had a weight loss comparable to that of mice receiving immu-
nization with saline. Depletion of CD8+ cells alone also reduced
protection while depletion of CD4+ T cells left protection intact.
These results were conﬁrmed in an experiment where
negatively selected T cells (Fig. S4B) from MIP1-NP or saline-
vaccinated mice were transferred to naïve mice. The next day, these
mice were challenged with a lethal dose of PR8 virus, and mice were
monitored for changes in weight (Fig. 5C and D).  Mice receiving
CD8+ T cells from the MIP1-NP vaccinated mice were signiﬁcantly
protected against PR8. In contrast, mice receiving CD4+ T cells had a
weight loss comparable to that of mice receiving T cells from saline
treated mice. Taken together, these data demonstrate that CD8+ T
cells play a crucial role in protection against heterochallenge with
inﬂuenza PR8 virus after vaccination with MIP1-NP.
4. Discussion
The hemagglutinin and neuraminidase surface proteins of
inﬂuenza virus represent commonly used targets for vaccine devel-
opment. However, responses against these proteins are dominated
by highly strain-speciﬁc antibodies. Since the surface proteins are
prone to antigenic drift, annual vaccine updates are needed to
effectively counter the circulating inﬂuenza strains. Due to the
long vaccine production time needed for current vaccine strate-
gies, it has to be decided almost a year ahead of deployment which
inﬂuenza strains are to be included in next year’s vaccines. The
strain selection is based on global surveillance data, but neverthe-
less constitutes an educated guess [2,42]. During years of vaccine
mismatch, or in the dire event of an antigenic shift causing pan-
demic inﬂuenza disease, the selected vaccines will likely provide
little protection to the population. Thus, vaccines capable of medi-
ating broader protection are needed.
In contrast to the highly variable surface proteins of inﬂuenza
virus, internal proteins are more conserved. Thus, the latter are
attractive for development of cross-protective vaccines that elicit
T cells that confer protection year after year. While T cells cannot
induce sterilizing immunity against inﬂuenza, they can greatly ease
the clinical course of an infection. T cell protection could therefore
be of particular beneﬁt to the population during years of conven-
tional vaccine mismatch. Also, broadly ﬂu-reactive T cells could
contribute some basic protection in the event of a pandemic.
T cell responses are thought to represent the main mechanism
of protection when using NP as vaccine antigen, and it has previ-
ously been shown that NP-speciﬁc T cells can transfer protection
to naïve mice [25,43]. Furthermore, depletion of NP-speciﬁc T cells
in vaccinated mice has been shown to abolish protection [24,25].
Recently, it has also been demonstrated that NP is a major target for
immunodominant CD8+ T cell responses during an inﬂuenza infec-
tion [44,45], and since humans typically are repeatedly exposed tocontinuously maintained. Vaccination with NP could in such a situ-
ation even more readily boost responses to reach protective levels,
as compared to vaccination of naïve humans or mice. Enhancement
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Fig. 5. CD8+ T cells are the prime mediators of protection after vaccination with MIP1˛-NP (A and B) BALB/c mice were immunized with 25 g MIP1-NP (n = 6 mice/group).
From  day 11 and until termination of the experiment, mice were injected every other day with depleting mAbs against either CD4, CD8, or both. A group of control mice were
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f Th1 responses and the induction of cytotoxic T lymphocytes
gainst NP thus constitute a sound strategy for the development
f more broadly protective inﬂuenza vaccines. Here, we describe
 DNA vaccine against inﬂuenza that induces T cells reactive to
P. The DNA vaccine encodes a protein that by use of MIP-1
hemokine bivalently targets NP to CCR1/3/5 chemokine recep-
ors on APC. This strategy enhances T cell responses to NP and
nduces heteroprotection against viral challenge. Protection is due
o vaccine-induced increase in CD8+ T cell responses, and antibod-
es appears to play little role.
Natural inﬂuenza infections and vaccination with NP can lead
o the induction of NP speciﬁc antibodies. Since such antibodies
re speciﬁc for an internal protein, they do not prevent viral entry
nto host cells. However, some recent studies have indicated that
on-neutralizing NP antibodies can contribute to heterosubtypic
mmunity against inﬂuenza [44,46–48]. Here, we found no cor-
elation between the induced antibodies and protection against
nﬂuenza.
+CD4 T cells play an important role in survival and responsive-
ess of memory CD8+ T cells [49,50], and memory CD4+ T cell
esponses towards NP have been described a signiﬁcant factor in
uman immune responses towards inﬂuenza infections [51–54].(C-D) BALB/c mice were immunized with 25 g MIP1-NP/EP. 12 days later, CD4+
ed into naive mice (n = 6 mice/group). A group of control mice received T cells from
2).
Whether induced by vaccination or infection, CD4+ T cells can
secrete cytokines (IFN, interleukin 2 (IL-2) and tumor necrosis
factor- (TNF)) that promote induction of cytotoxic CD8+ T cells.
Here, we have found that protection against inﬂuenza can be trans-
ferred with CD8+ T cells, but not CD4+ T cells. However, this does
not exclude an initial role of CD4+ T cells in helping NP-speciﬁc
CD8+ T cell responses during the induction phase.
Previously, others have conducted DNA vaccination experi-
ments where NP vaccination has protected mice against inﬂuenza.
However, efﬁcacy was  dependent on large DNA doses, the inclusion
of adjuvants, and multiple immunizations [5,24,55,56]. Efﬁcacy of
DNA vaccination is a challenge to clinical translation, and the few
trials conducted in humans with NP have been based on viral gene
delivery, using either the Modiﬁed Vaccinia virus Ankara (MVA)
vector [57] or a replication-deﬁcient chimpanzee adenovirus vec-
tor (ChAdOx) [58]. While increasing vaccine efﬁcacy to a single
immunization, immune responses to the viral vector may preclude
multiple immunizations. Also, viral gene delivery may  pose risks
due to the possibility of random insertion sites, cytopathic effects,
and mutagenesis [59].
Interestingly, the selected target on an APC may inﬂuence the
polarization of immune responses induced by the vaccine. Thus,
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hereas targeting to MHC  class II molecules was previously found
o promote antibodies and Th2 responses, delivery to CCR1/3/5
romoted Th1 responses and cytotoxic T cells [31,33,60,61]. The
resent results conﬁrm these previous results and extend the
h1/CD8 polarization effect to the conserved internal inﬂuenza pro-
ein NP, to which T cell responses may  be of special signiﬁcance. The
ncreased efﬁcacy of MIP-1-targeted DNA vaccines in mice may  be
xtended to larger animals and humans, since a human homolog
o the murine MIP-1 (LD78)  can be used to target human CCR1
nd 5 chemokine receptors [39]. Thus, further studies with MIP-1
NA vaccines in larger animals should be feasible.
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